Nigeria Vaccinates over 45 Million People Against Yellow Fever During the COVID-19 Pandemic

1 0
Read Time:3 Minute, 40 Second

In 2016, deadly outbreaks of yellow fever in Angola and the Democratic Republic of the Congo, with spread to China, put the African continent on notice for this disease

New films show the impact of yellow fever outbreaks in Taraba State, and the global efforts to eliminate yellow fever epidemics by 2026.

“I lost my second child to yellow fever. It was a very traumatising experience for my family and I,” explains Muhammed Awal, a father of five from Taraba State. “We rushed the child to hospital when he started showing symptoms of the disease, and he died two to three days after, because his internal organs had been very damaged.”

Muhammed describes his family’s tragedy and efforts to ensure protection for the rest of his children in one of two films commissioned by the Eliminate Yellow Fever Epidemics Strategy or EYE. EYE’s goal is to eliminate yellow fever epidemics by 2026, through a single-shot vaccine that gives lifelong immunity, and aims to protect almost 1 billion people in Africa and the Americas.

In 2016, deadly outbreaks of yellow fever in Angola and the Democratic Republic of the Congo, with spread to China, put the African continent on notice for this disease. The EYE Strategy, a partnership between the World Health Organization, UNICEF and Gavi, the Vaccine Alliance, was set up in response and identified Nigeria as a high-risk country.

Nigeria’s population is around 200 million people, with 160 million people at risk of yellow fever. This makes up around 25% of all the people at risk in Africa.  Yellow fever is a virus transmitted by infected mosquitoes. Dr Anne Eudes Jean Baptiste, Medical Officer for the World Health Organization Nigeria explains, “yellow fever is dangerous because a small percentage of patients will go through a more toxic phase of the disease. By then they will experience fever, have system failure, mainly in the kidney and liver. They may experience bleeding coming from the mouth, nose and eyes and within 7 to 10 days, half of them will die.”

Home to some of the world’s most densely populated cities, Nigeria is at risk of both urban and sylvatic (jungle) exposure to the disease. Sylvatic exposure is the transmission of yellow fever from mosquitos that have bitten animals and non-human primates. Workers in mining and agriculture are particularly vulnerable to this type of transmission.

Despite the ongoing COVID-19 pandemic, we have given out over 66 million doses* in 2020 and 2021 to protect people from yellow fever outbreaks

In 2017, there was a resurgence in yellow fever in Nigeria after 15 years. This is due to gaps in detection of the disease rather than lack of transmission of the virus and the cyclical nature of sylvatic transmission. As surveillance and laboratory testing have been strengthened, improved information about the distribution of the disease in humans has become available.

Dr Ifedayo M. O Adetifa, Director General of the Nigeria Center for Disease Control, explains, “we have strengthened surveillance considerably. We have reference laboratories in the country that have been strengthened, and are being supported and assessed to make sure they are meeting all the performance parameters in terms of sample collection and referral to our reference labs in Abuja.”

“Despite the ongoing COVID-19 pandemic, we have given out over 66 million doses* in 2020 and 2021 to protect people from yellow fever outbreaks. This achievement has been possible through routine immunization, as well as mass vaccination campaigns that identify gaps in the population and proactively target vulnerable communities.”

Dr Adetifa features in a second film that documents the roll-out of a vaccination campaign in Taraba State, and brings to light the global effort required to keep Nigerians safe.

*This number was estimated at the time of the filming. Actual number for preventive and reactive mass vaccination campaigns is 45 million during the COVID-19 pandemic.

Both films can be viewed here:

An infographic on Nigeria’s recent history with yellow fever can be found here:

Further information on the EYE Strategy and yellow fever can be found here:

  • Yellow fever (who.int)
  • Eliminate yellow fever epidemics (EYE) strategy 2017-2026 (who.int)

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %

About Author

You may have missed

Lusaka — African health ministers and partners are calling for increased investment in integrated health services to address the growing burden of severe noncommunicable diseases (NCDs), particularly those affecting women and underserved populations across the region. At a high-level side event during the Seventy-fifth session of the WHO Regional Committee for Africa, delegates emphasized the urgent need for equitable access to prevention, screening, treatment, and rehabilitation across the continuum of care for NCDs. Disparities are especially pronounced in rural areas, where health infrastructure and services remain inadequate. Breast and cervical cancers are among the leading causes of cancer-related deaths among women in sub-Saharan Africa—particularly cervical cancer, which is both preventable and treatable. It remains the most common cause of cancer death for women in the region. In 2022, Africa accounted for nearly a quarter (23%) of the 76 000 global cervical cancer deaths. Meanwhile, severe NCDs such as Type 1 diabetes, sickle cell disease, and heart conditions claim more than half a million lives annually, including among children, adolescents, and young adults in some of the continent’s poorest communities. Inequitable access to health services continues to hinder efforts to reduce this burden. To improve cervical and breast cancer care in the region, urgent investment is needed in leadership, governance, and financing. Strengthening these foundations is critical in the current funding landscape. Advancements in strategic planning, healthcare infrastructure, workforce training, and—most importantly—equitable access to screening, diagnostic, and treatment services are essential. To address these challenges, WHO and its partners showcased successful integrated models such as the Women’s Integrated Care for Cancer Services (WICS), the BEAT Breast Cancer Project, and the PEN-Plus Strategy. WICS strengthens early detection, treatment, and integration of women’s cancer services into primary health care systems in Côte d’Ivoire, Kenya, and Zimbabwe. The BEAT Breast Cancer Project is a transformative multi-year initiative aimed at reducing breast cancer mortality among women in Tanzania and Ghana through early detection, timely diagnosis, and comprehensive treatment access. “PEN-Plus, WICS and the BEAT Breast Cancer Initiative are models for a new standard of care, rooted in equity, access and health justice. I urge countries to prioritize policies that embed these models into broader health system strengthening, said Dr Mohamed Janabi, WHO Regional Director for Africa”. Côte d’Ivoire offers a compelling example of progress, combining high HPV vaccination coverage—reaching over three million girls (91.4%)—with WICS-supported community-based screening campaigns to strengthen cervical cancer prevention. In Kenya, cervical cancer screening has been successfully integrated into national health services. “This gathering marks a pivotal moment to accelerate action for breast cancer prevention in Africa. We deeply value the leadership of the Ministries of Health of Ghana and Tanzania, and the steadfast support of the Pfizer Foundation in helping us achieve this milestone. The side event builds momentum for the policy prioritization of women’s cancers, partnerships to strengthen the broader women’s cancer ecosystem, and advance a health-systems approach to breast cancer prevention and management”, said Dr Somesh Kumar, Senior Director, Jhpiego. PEN-Plus expands access to care for severe NCDs at the district hospital level. Since its implementation, 20 countries in Africa have increased access to services for severe NCDs. Over 15 000 people are currently receiving treatment for chronic conditions such as sickle cell disease and Type 1 diabetes through PEN-Plus clinics.